Navigation Links
Adalimumab Proves Effective for Children with Juvenile Rheumatoid Arthritis

Adalimumab, an injectable anti-TNF therapy that has FDA approval for treating rheumatoid arthritis in adults, has proven effective in children with juvenile rheumatoid// arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington, DC.

The immunosuppressant adalimumab, currently used to treat adults with moderate to severe rheumatoid arthritis, targets inflammation by blocking TNF (tumor necrosis factor) proteins in the body. Following studies that demonstrated safety and effectiveness in adults with rheumatoid arthritis, this study in children with juvenile rheumatoid arthritis was performed. Juvenile rheumatoid arthritis affects an estimated 285,000 children in the U.S. The disease, which starts before they reach age 16, can cause joint stiffness, reluctance or refusal to use arms or legs, reduced activity levels, persistent pain and joint swelling. If not effectively treated, it can result in joint damage, growth delay and decreased bone mineralization.

To assess the long-term effectiveness and safety of adalimumab in a younger population, researchers conducted a 48-week randomized study on 171 children, ages 4 to 17, with five or more swollen joints and three or more joints with limited range of motion at the outset of the study. The subjects were categorized as those taking and not taking methotrexate at the beginning of the study. The dose of methotrexate and all other arthritis medications remained stable throughout the trial. Adalimumab doses were based on the child’s size, with participants receiving 24 mg/M2 BSA, maximum of 40 mg, given as a subcutaneous injection every 2 weeks over a 16-week period. At the end of the 16 weeks, the 83% (142) of the subjects who met the definition of “responder” for this study were randomized into a double-blind study and assigned to either continue adalimumab or switch to a placebo for the next 32 weeks or until disease flare-u p.

Results demonstrated that participants receiving adalimumab had significantly fewer disease flares than those on placebo. Of those not already taking methotrexate, 43% randomized to adalimumab and 71% to placebo flared; of those already on methotrexate, 37% and 65%, respectively flared. The most common problems were mild upper respiratory infections. No tuberculosis or opportunistic infections were reported.

“Based on this data, adalimumab taken with or without methotrexate provided rapid, substantial and sustainable improvement for children with very active juvenile rheumatoid arthritis,” explains Daniel J. Lovell, MD, MPH, Chairman, Pediatric Rheumatology Collaborative Study Group, Cincinnati, Ohio and an investigator in the study. “Given that the medication was generally well tolerated, adalimumab has emerged as an excellent treatment option for children with juvenile rheumatoid arthritis.”


Related medicine news :

1. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
2. Study Proves That MMR Vaccine Is Not Connected To Autistic Babies
3. Pilot Study Proves Home Abortions ‘Safe’
4. Many Nonprescription Cough Medicines Proves Ineffective
5. Less Invasive By Pass Surgery Proves Economical In The Long Run
6. Epidural Mistakes Proves To Be Fatal Blunders
7. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
8. Drug Trial Proves Nightmare for British Indian Student
9. Naturopathic Care Proves Beneficial for TMD Pain
10. Medtronic Device Proves Effective in Parkinson’s Diseas
11. Large Community Spirometry Screening Proves Successful
Post Your Comments:

(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
(Date:11/25/2015)... ... 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna ... and far-infrared saunas. , For traditional saunas, Finnleo is offering 20% ... wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... sauna parts and accessories. , Sauna accessories help improve the bather experience in ... personality. From basic styles for the purist looking for simplicity in design to ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
Breaking Medicine Technology: